Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
May 16, 2013 -- Credentis ag in collaboration with its research partners presented further clinical data on the efficacy of biomimetic mineralization with Curodont™ Repair in the treatment of early proximal and buccal caries, as well as data elucidating the mechanistic action of the Curolox™ Technology, showing in-depth biomimetic mineralisation both in vitro and in vivo. “The presentation of the clinical data on Curodont™ Repair validates the data obtained in the Proof-of-Concept clinical study. In combination with the data from the detailed analysis on the mechanism of action, it presents a milestone for credentis, showing the in-depth effect of the carious treatment”, says credentis CEO Dr Dominik Lysek.
Curodont™ and the Curolox™ technology
The patented Curolox™ technology is based on peptides self-assembling into a matrix triggering a biomimetic mineralisation and repair mechanism. The technology is the basis of all credentis’ innovative products.
Curodont™ Repair provides dentists with a non-invasive option for natural mineralisation rather than classical repair of carious lesions. Applied to an early lesion Curodont™ Repair forms a scaffold within the lesion around which new hydroxyapatite can form and grow. Ideally, within several weeks the lesion will mineralise. This effect is observed in a growing number of patients both in clinical studies and daily practice settings. Curodont™ Protect uses the Curolox™ technology to protect the tooth surface from acid attack or to treat unpleasant tooth sensations.
“The presentation of the clinical data and the verification of the data obtained in the Proof-of-Concept clinical study presents a milestone for credentis, as it shows the in-depth treatment of the tooth decay. credentis seeks to support with its regenerative product line a trend towards prevention and early treatment. Curodont™ Repair has its potential in the treatment of early dental caries, whereas Curodont™ Protect has its main benefit in prophylaxis and in the treatment of dentin hypersensitivity!” explains CEO Dominik Lysek. The ultimate goal is to prevent caries by the use of its regenerative product line and frequent dental recalls by dentists and dental hygienists.
About credentis ag
credentis ag is headquartered in the Technopark Aargau Switzerland, Windisch. credentis has won multiple startup awards as well as support from startup organizations like Genilem and multiple public grants incl. Swiss National Fonds, Aargauer Forschungsfond and the Medical Technologies IKC together with the University of Leeds.
CEO Dominik Lysek, CTO Michael Hug and CBO Tobias Feger have a strong track record in medicinal technology, marketing and a strong network in the dental industry. credentis board members Dr. Werner Berner and Dr. Erich Platzer (chairman), both members of the StartAngels Network, contribute their expert knowledge of industry and finance.
Help employers find you! Check out all the jobs and post your resume.